No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, ...

Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that the U.S. Food & Drug Administration (FDA) has ...

The results were alarming. Among PPI users, 5.6% reported kidney-related problems, compared to just 0.7% of those taking ...

Young people are experiencing distressing symptoms of sexual dysfunction and emotional numbness following antidepressant ...

New study shows dementia patients who are on antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), ...

Scientists at the (UNIGE) have developed a tool that uses light to precisely control where and when a drug becomes active, ensuring it works exactly where it's needed. For medical treatments to be ...

The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

A newly published review in Genes & Diseases explores the oncogenic activation of PIK3CA in cancer and highlights emerging ...

Swedish scientists examining 19,000 patients taking antidepressants experienced changes in their brain function compared to ...

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding it ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...